Market

Glenmark Pharma shares hit 52-week low as global brokerages cut target after weak Q1

Updated : August 16, 2019 12:45 PM IST

Shares of Glenmark Pharma fell 6 percent to its 52-week low of Rs 360.35 on Friday on poor June quarter results.

The sentiment was further affected as global brokerages cut their 12-month target price for the stock post the earnings.

Glenmark Pharma reported a 53 percent year-on-year (YoY) fall in its consolidated net profit at Rs 109.28 crore as against Rs 233 crore a year ago.

Glenmark Pharma shares hit 52-week low as global brokerages cut target after weak Q1

Shares of Glenmark Pharma fell as much as 6 percent to a 52-week low of Rs 360.35 on Friday, as global brokerages slashed price target on the stock after weak June-quarter earnings.

At 12:23 PM, the stock was trading 5 percent lower at Rs 364 per share on the BSE as compared to a 0.12 percent (46 points) gain in Sensex.

Glenmark Pharma reported a 53 percent year-on-year (YoY) fall in its consolidated net profit at Rs 109.28 crore despite a one-time forex gain of Rs 138.21 crore. Meanwhile, consolidated revenue grew 7.3 percent YoY to Rs 2,322.87 crore in Q1.

“Our first-quarter performance in key markets like India and Europe was impressive on account of new product launch and partnership deals. However, the overall performance was impacted due to moderate performance in the US and subdued performance in Latin America,” Glenn Saldanha, Chairman and MD at Glenmark Pharmaceuticals, said in a statement.

Global brokerages CLSA and Credit Suisse cut their price targets for the stock following Q1 earnings.

CLSA maintained a 'sell' call on the stock but slashed target price to Rs 350 per share from Rs 500 earlier as it expects earnings growth to remain under pressure. The brokerage also cut its FY20-21 EPS estimates by 15-18 percent.

Credit Suisse, however, retained its 'neutral' rating on the stock but reduced target price to Rs 415 per share from Rs 600 earlier. It also cut the stock's FY20/21 EPS estimates by 24/16 percent to factor in weak Q1.

The US recovery will be driven by two new launches in Q2 and Novartis deal will help recovery in Brazil, as per Credit Suisse.

Also, track all live market action on CNBC-TV18 Market Blog

Disclaimer: CNBCTV18.com advises users to check with certified experts before taking any investment decisions

Have you signed up for Primo, our daily newsletter?

It has all the stories and data on the market, business, economy and tech that you need to know.

To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more